Dietary Supplements Linked to One Death; Pose Risk of Liver Injury.

The U.S. Food and Drug Administration is warning consumers to immediately stop using Hydroxycut products by Iovate Health Sciences Inc., of Oakville, Ontario and distributed by Iovate Health Sciences USA Inc. of Blasdell, N.Y. Some Hydroxycut products are associated with a number of serious liver injuries. Iovate has agreed to recall Hydroxycut products from the market.

The FDA has received 23 reports of serious health problems ranging from jaundice and elevated liver enzymes, an indicator of potential liver injury, to liver damage requiring liver transplant. One death due to liver failure has been reported to the FDA. Other health problems reported include seizures; cardiovascular disorders; and rhabdomyolysis, a type of muscle damage that can lead to other serious health problems such as kidney failure.

Liver injury, although rare, was reported by patients at the doses of Hydroxycut recommended on the bottle. Symptoms of liver injury include jaundice (yellowing of the skin or whites of the eyes) and brown urine. Other symptoms include nausea, vomiting, light-colored stools, excessive fatigue, weakness, stomach or abdominal pain, itching, and loss of appetite.

“The FDA urges consumers to discontinue use of Hydroxycut products in order to avoid any undue risk. Adverse events are rare, but exist. Consumers should consult a physician or other health care professional if they are experiencing symptoms possibly associated with these products,” said Linda Katz, M.D., interim chief medical officer of the FDA’s Center for Food Safety and Applied Nutrition.

Hydroxycut products are dietary supplements that are marketed for weight-loss, as fat burners, as energy-enhancers, as low carb diet aids, and for water loss under the Iovate and MuscleTech brand names. The list of products being recalled by Iovate currently includes:

• Hydroxycut Regular Rapid Release Caplets
• Hydroxycut Caffeine-Free Rapid Release Caplets
• Hydroxycut Hardcore Liquid Caplets
• Hydroxycut Max Liquid Caplets
• Hydroxycut Regular Drink Packets
• Hydroxycut Caffeine-Free Drink Packets
• Hydroxycut Hardcore Drink Packets (Ignition Stix)
• Hydroxycut Max Drink Packets
• Hydroxycut Liquid Shots
• Hydroxycut Hardcore RTDs (Ready-to-Drink)
• Hydroxycut Max Aqua Shed
• Hydroxycut 24
• Hydroxycut Carb Control
• Hydroxycut Natural

Although the FDA has not received reports of serious liver-related adverse reactions for all Hydroxycut products, Iovate has agreed to recall all the products listed above. Hydroxycut Cleanse and Hoodia products are not affected by the recall. Consumers who have any of the products involved in the recall are advised to stop using them and to return them to the place of purchase. The agency has not yet determined which ingredients, dosages, or other health-related factors may be associated with risks related to these Hydroxycut products. The products contain a variety of ingredients and herbal extracts.

Health care professionals and consumers are encouraged to report serious adverse events (side effects) or product quality problems with the use of these products to the FDA’s MedWatch Adverse Event Reporting program online, by regular mail, fax or phone.

The FDA continues to investigate the potential relationship between Hydroxycut dietary supplements and liver injury or other potentially serious side effects.

Today, Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), announced that it has begun a voluntary, phased withdrawal of the product from the U.S. market. The company is taking this action because of a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML), a rare, serious, progressive neurologic disease caused by a virus that affects the central nervous system. By June 8, 2009, Raptiva will no longer be available in the United States.

Prescribers are being asked not to initiate Raptiva treatment for any new patients. Prescribers should immediately begin discussing with patients currently using Raptiva on how to transition to alternative therapies. The FDA strongly recommends that patients work with their health care professional to transition to other alternative therapies for psoriasis.

The risk that an individual patient taking Raptiva will develop PML is rare and is generally associated with long-term use. Generally, PML occurs in people whose immune systems have been severely weakened and often leads to an irreversible decline in neurologic function and death. There is no known effective treatment for PML. On Oct. 16, 2008, FDA updated the FDA-approved labeling for Raptiva to warn of the risk of life-threatening infections, including PML. On Feb. 19, 2009, the FDA issued a Public Health Advisory informing patients and prescribers of the risk of PML in patients taking Raptiva, after receiving reports of four patients with PML, three of whom died. On March 13, 2009, the FDA approved a Medication Guide for Raptiva and included additional information in Raptiva’s labeling regarding PML.

Raptiva was approved by the FDA in 2003. It is a once-weekly injection for adults with moderate to severe plaque psoriasis.

Prescribers should continue to monitor patients on Raptiva for neurologic symptoms that might represent PML.

Agency Warns Against Chronic Use of These Products to Treat Gastrointestinal Disorders.

The U.S. Food and Drug Administration announced today that manufacturers of metoclopramide, a drug used to treat gastrointestinal disorders, must add a boxed warning to their drug labels about the risk of its long-term or high-dose use. Chronic use of metoclopramide has been linked to tardive dyskinesia, which may include involuntary and repetitive movements of the body, even after the drugs are no longer taken.

Manufacturers will be required to implement a risk evaluation and mitigation strategy, or REMS, to ensure patients are provided with a medication guide that discusses this risk.

The FDA wants patients and health care professionals to know about this risk so they can make informed decisions about treatment, said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research. The chronic use of metoclopramide therapy should be avoided in all but rare cases where the benefit is believed to outweigh the risk.

Current product labeling warns of the risk of tardive dyskinesia with chronic metoclopramide treatment. The development of this condition is directly related to the length of time a patient is taking metoclopramide and the number of doses taken. Those at greatest risk include the elderly, especially older women, and people who have been on the drug for a long time.

Tardive dyskinesia is characterized by involuntary, repetitive movements of the extremities, or lip smacking, grimacing, tongue protrusion, rapid eye movements or blinking, puckering and pursing of the lips, or impaired movement of the fingers. These symptoms are rarely reversible and there is no known treatment. However, in some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.

Metoclopramide works by speeding up the movement of the stomach muscles, thus increasing the rate at which the stomach empties into the intestines. It is used as a short-term treatment of gastroesophageal reflux disease in patients who have not responded to other therapies, and to treat diabetic gastroparesis (slowed emptying of the stomach’s contents into the intestines). It is recommended that treatment not exceed three months.

Metoclopramide is available in a variety of formulations including tablets, syrups and injections. Names of metoclopramide-containing products include Reglan Tablets, Reglan Oral Disintegrating Tablets, Metoclopramide Oral Solution, and Reglan Injection. More than two million Americans use these products.

Recently published analyses suggest that metoclopramide is the most common cause of drug-induced movement disorders. Another analysis of study data by the FDA showed that about 20 percent of patients in that study who used metoclopramide took it for longer than three months. The FDA has also become aware of continued spontaneous reports of tardive dyskinesia in patients who used metoclopramide, the majority of whom had taken the drug for more than three months.

Patients who use the drug Reglan may be at risk to movement disorders and a condition known as tardive dyskinesia. Recently published analyses suggest that Reglan, also known as metoclopramide, is the most common cause of drug-induced movement disorders. The FDA also reports continued spontaneous cases of tardive dyskinesia in patients who used metoclopramide, the majority of whom had taken the drug for more than three months. Over two million Americans use these products for the treatment of a number of gastrointestinal disorders and more cases of movement disorders and tardive dyskinesia are expected to be reported.

Tardive Dyskinesia Symptoms

Twitching	Abnormal head movements
Involuntary facial movements	Tongue protrusions
Lip smacking	Lip puckering
Rapid eye movements	Excessive eye blinking
Frowns and grimacing expressions	Shaking of hands
Shaking of feet	Other injuries

Reglan Tardive Dyskinesia Lawsuit

Reglan users who suffer severe side effects may seek damages in tardive dyskinesia lawsuits. Reglan patients who may have tardive dyskinesia should talk to a trial lawyer about a Reglan side effect, or metoclopramide side effects, lawsuit concerning their Parkinson-like tremors. More information is available here: Reglan Side Effects Lawsuit.

Speak to a Reglan Lawyer

If you or a loved one has taken Reglan (metoclopramide) for more than twelve consecutive weeks and currently suffer from some of the symptoms of tardive dyskinesia or have been diagnosed with tardive dyskinesia, then you may be entitled to recover monetary damages for your injuries. Contact the Willis Law Firm to speak to an experienced product liability lawyer about your legal rights against the manufacturer(s) of Reglan or generic metoclopramide.

You are not alone. Join other tardive dyskinesia victims in speaking up and fighting for their legal rights. Please fill out our free legal evaluation form on the right side of this page and we will call or e-mail you back within 24 hours. Please keep in mind that certain states have a statute of limitations that limits the amount of time you have to file a lawsuit or seek legal action, so don’t wait to contact our law firm. All cases are taken on a Contingency Fee Basis (No fees or expenses are charged to the client by the attorneys, unless there is a recovery made for you.)

Posted below is an article reprint of a paper written by Patricia Walter, including contributions from various hip resurfacing surgeons.  This article addresses the medical condition which some doctors call: tissue reaction pseudotumors, AVAL – aseptic lymphocyte dominated vasculitis associated lesion and others simply call metalosis.  These are complications that may occur following hip resurfacing surgery utilizing a metal-to-metal-bearing hip resurfacing device  made of  high carbon cobalt-chromium alloys.

by Patricia Walter and Hip Resurfacing Surgeons

Updated 1/9/09

Patients and prospective patients are always concerned about the complications that could occur after a hip resurfacing surgery. The typical problems include femur neck fractures, dislocations, loose acetabular cups, improperly positioned acetabular cups, high metal ions, infections, pseudotumors, ALVAL and metalosis.

There has been a lot of discussion among patients on discussion groups about the high metal ion issue and pseudotumors.  I am not a doctor or medically trained.  I am a Patient Advocate, Hip Resurfacing Patient and Mechanical Engineer.  I had the opportunity to attend the  Second Annual U.S. Comprehensive Course on Total Hip Resurfacing Arthroplasty October 24–25, 2008 Los Angeles, CA.  I listened to discussions about the metal ion issues and pseudotumors. I am going to explain what I learned in simple, non-medical terms since that is all I can do.

As an observer, I learned that the high metal ion issue has occurred in a small number of cases as a post op problem after a hip resurfacing. One of the most likely reasons, according to the experienced surgeons and presenters at the course, was the incorrect placement of the acetabular cup which resulted in additional wear on the bearing surface between the acetabular cup and the femur cap component.  The hip resurfacing device is really a metal bearing made of  High Carbon Cobalt-Chromium alloys.  A bearing is designed to equally spread out the load over the load bearing components.  If the components are not aligned properly, then only part of the bearing is loaded resulting in much more wear in that area possibly causing a high metal ion level. It was also explained that women seem to have more problems with high metal ions than men. Perhaps, this is due to the fact that most women use smaller sized hip resurfacing devices which causes more loading on the bearing surfaces than the men’s larger sized devices.

When there is an abnormally high metal ion release from misplaced components, it seems to cause the surrounding tissue and bone to react adversely.  The surrounding tissue and bone tends to become abnormal.  Some doctors call the tissue reaction pseudotumors, AVAL (aseptic lymphocyte dominated vasculitis associated lesion), & others call it metalosis.  Whatever name given to the abnormal reaction, it is not good to have this happening around the hip device since it could become loose, pain could result  and possibly more severe medical reactions could happen. 

There is concern among the hip resurfacing community about the reactions to the very high metal ion issue.  At this time, to my understanding, there is not a standardized blood test available.  Different labs use different methods and tests.  There are not yet any specific guidelines as to what levels are too high for metal ions.  There is a lot of research being done, but there are no standards yet. 

This makes a surgeon’s job to define and solve problems due to high metal ions difficult.  Some doctors feel that patients with very high metal ions should have a revision of their hip resurfacing to a ceramic on ceramic THR.  They don’t want to take chances that even more serious problems could develop due to the high metal ions.  Normally, from what I understand, the high metal ions are probably due either to the incorrect position of the acetabular cup causing very high wear on the hip resurfacing bearing device or due to the use of a small hip resurfacing device causing excessive loading on the bearing surfaces. So once again, the learning curve and experience of hip resurfacing surgeons is very important to prospective patients along with proper patient selection.  It takes a great deal of experience to consistently place the acetabular cups at the proper angle and to know which smaller patients can successfully receive a hip resurfacing.

That is my layman’s explanation of the high metal ion issue.  I am posting a number of abstracts below by surgeons attending the Second Annual U.S. Comprehensive Course on Total Hip Resurfacing Arthroplasty October 24–25, 2008 Los Angeles, CA. Their articles will help explain more about the high metal ion issue, the small device issue used in many women and the acetabular cup placement issue.

Presented at the Second Annual U.S. Comprehensive Course on Total Hip Resurfacing Arthroplasty October 24–25, 2008 Los Angeles, CA

Joshua J. Jacobs, M.D.Professor and Chairman, Department of Orthopaedic SurgeryRush University Medical CenterChicago, IL

Recently there have been reports that there is a unique histological response in patients with metal on metal bearings in which there is a prominent perivascular and/or diffuse lymphocytic infiltration that is reminiscent of a delayed type hypersensitivity response. This response has been termed ALVAL (aseptic lymphocyte dominated vasculitis associated lesion) and it is reported around metal-on-metal implants from various manufacturers. This issue is not completely understood and the incidence of individuals requiring revision for an apparent hypersensitivity to otherwise well functioning meta lon-metal bearings is currently unknown, but thought to be relatively low. Recent clinical reports have suggested a link between early osteolysis in patients with metal-on-metal bearing total hip replacement systems and metal hypersensitivity, based on either patch testing or histological evidence of so-called ALVAL. In addition, there are reports of pseudotumors occurring in association with metal on metal bearings that may be independent of the ALVAL phenomenon.

Degradation products either in the form of ionic or particulate debris can complex with local proteins, which alters their confirmation and elicits an allergic response comparable with a delayed type hypersensitivity response (Type IV). This type of hypersensitivity is mediated by T lymphocytes reactive against metal ion-modified self-proteins. This provides the primary stimulus to the immune response. To respond with an immune response, the T lymphocyte must also get a secondary stimulus. This is classically provided by co-stimulatory molecules, which are classified to soluble and cell membraneboundco-stimulatory molecules. When the T lymphocyte is responding to both primary and secondary stimulus, it will become sensitized starting antigen-driven clonalproliferation and differentiation. In this paradigm, there is co-operation between innate and adaptive immunity. There is some evidence that patients with metal on metal bearings and/or high serum metal levels elicit more response to metal antigen challenge measured as either patch test sensitivity or lymphocyte proliferation. Thus, while there is an idiosyncratic aspect of the allergic response, there is also a dose response component.

Presented at the Second Annual U.S. Comprehensive Course on Total Hip Resurfacing Arthroplasty October 24–25, 2008 Los Angeles, CA

David W. Murray, MD, FRCS (Orth)Nuffield Hospital, Department of Orthopaedic Surgery University of Oxford Headington, Oxford OX3 7LD UK

A number of patients who have metal-on-metal resurfacing have various symptoms and a soft-tissue mass which we termed a pseudotumour. We report 20 cases. Each patient underwent plain radiography and in some, CT MRI and ultrasonography were also performed. In addition, histological examination of available samples was undertaken. All the patients were women and their presentation was variable. The most common symptom was discomfort in the region of the hip. Other symptoms included spontaneous dislocation, nerve palsy, a noticeable mass or a rash. The common histological features were extensive necrosis and lymphocytic infiltration. To date, 13 of the 20 hips have required revision to a conventional hip replacement. Two are awaiting revision. We estimate that approximately 1% of patients who have a metal-on-metal resurfacing develop a pseudotumour within five years. The cause is unknown and is probably multifactorial. There may be a toxic reaction to an excess of particulate metal wear debris or a hypersensitivity reaction to a normal amount of metal debris. We are concerned that with time the incidence of these pseudotumours may increase. Further investigation is required to define their cause.

Presented at the Second Annual U.S. Comprehensive Course on Total Hip Resurfacing Arthroplasty October 24–25, 2008 Los Angeles, CA

Michael Antony Tuke Finsbury Orthopaedics Ltd.13 Mole Business Park, Randalls Road Leatherhead, Surrey KT22 7BA UK

Acetabular cup placement has been established by long term wisdom at an abduction angle around 45 degrees and anteversion of around 15 degrees. Achieving this position is not an exact science and falls to most surgeons’ judgment case by case. The result is a very wide ranging variation of position. It has become apparent that large ball Metal on Metal implants are particularly susceptible to high wear if placed too open such that edge load bearing occurs. The reduced dislocation rate demonstrated by large balls may have reduced the sense of importance for careful cup placement…

…In addition to this the design of these cups normally provides for a reduced centre edge angle relative to more established cups that have demonstrated good placement at 45degrees abduction. The effective angle of the critical edge that can cause run away wear can be as much as 18 degrees more open than might be expected if placed at 45 degrees. The cup face and introducer placed at 45 degrees will thus place the cup more “open” than is appreciated by the surgeon…

Presented at the Second Annual U.S. Comprehensive Course on Total Hip Resurfacing Arthroplasty October 24–25, 2008 Los Angeles, CA

Graham Isaac, PhD Institute of Medical and Biological Engineering School of Mechanical Engineering University of Leeds Leeds, LS2 9JT, UK

Background: There is continued concern over the long-term effects of wear products following hip replacement using metal-metal bearing surfaces. This study considers the effect of cup abduction angle on metal ion levels in a four-centre study of patients who had received the same surface replacement device.

Methods: Patients with a unilateral, low-profile, low clearance metal-metal resurfacing prosthesis (DePuy ASR™; DePuy; Leeds, UK) were recruited from four centres. Whole blood samples were collected, frozen and analyzed using high resolution ICP-MS. The acetabular lateral opening angle was measured on standard antero-posterior radiographs. Results: Forty-four patient were available for review at 24 month. The median ion levels were 1.49ug/l for both chromium and cobalt. This group comprised 34 males and 10females. There was significant variation in pre-operative levels and in the 38 patients in whom this value was available, the increase metal ion levels after 24 months were0.75ug/l and 0.97ug/l for chromium and cobalt respectively. In 58% of patients the increase in chromium level at 24 months from pre-operative levels was less than 1ug/l(53% for cobalt). However, after 24 months implantation there were 6 outliers with cobalt or chromium levels greater than 10 ug/l. Fifty percent of patients with a high lateral opening angle (>55°) had a metal ion level >10ug/l compared to 6% in those withal lower angle (<55°). Two of the four centres had a higher cup abduction angles (53°, 50°compared with 45°, 44°). Four out of the six outliers in this series were implanted at the centre with the highest mean cup abduction angle.

Conclusions: Large diameter metal bearings with low radial clearance can produce very low whole blood metal ion levels. However ion levels, and by inference wear, increase with acetabular lateral opening angle. Furthermore, component mal-position and its effect are not uniformly distributed across the four centres contributing to this study which suggests that the occurrence of high metal ions levels may be avoided by correct component position.

Presented at the Second Annual U.S. Comprehensive Course on Total Hip Resurfacing Arthroplasty October 24–25, 2008 Los Angeles, CA

Justin Peter Cobb, MD5 Devonshire Place London, W1G 6HL UK

Component positioning in each case should be based upon the individual’s pathology. The underlying disease process will determine the pathological positions and angulations that need to be corrected…

… Acetabular component positioning does not pose too many problems for the hip surgeon, save the restricted choice of component size depending on the head size. Femoral component positioning and sizing is the major issue.

Most commonly, this procedure is performed for cam type hips. To optimize the load transfer between head and neck in this condition, the component centre must first be translated anteriorly and superiorly, then angulated into greater valgus and anteversion. The socket should be translated posteriorly, inferiorly and deeper, with angulation optimized depending on gender and morphology…

…Individual cases may need variations at the limits of these parameters. If they cannot be achieved in preoperative planning, then total hip arthroplasty with a less demanding bearing couple may be more appropriate.

Common Femoral Misplacements:

Head in varus: will predispose to fatigue fracture Head inferior on neck: will predispose to neck notching and fracture

Head posterior on neck: will cause impingement in flexion and anterior notching

Head too large, centered on cam: makes the socket too big causing impingement

Head too small: Minimal room for error, neck on socket impingement can occur

Common Acetabular Misplacements:

Socket proud: excessive offset, leading to some pain and stiffness

Socket retroverted: may cause psoas impingement

Socket too anteverted and too steeply inclined: will cause an increased wear rate.

Presented at the Second Annual U.S. Comprehensive Course on Total Hip Resurfacing Arthroplasty October 24–25, 2008 Los Angeles, CA

John Antoniou, MD, PhD, FRCSC Jewish General Hospital3755 Cote-St. Catherine Road Room E-003Montreal, Quebec H3T 1E2 Canada

Evaluation and treatment of the painful total hip resurfacing arthroplasy can be challenging even for the most experienced arthroplasty surgeon. The possibility of metal sensitivity as a cause of persistent groin pain should always be considered in metal on metal resurfacing hip replacements. Additionally, iliopsoas tendinopathy, and anterior impingement of the hip joint are well recognised causes of pain and should be part of the differential diagnosis. Even though the exact clinical significance of the femoral neck narrowing and the incidence of femoral head osteonecrosis are still largely unknown, surgeons should be monitoring the radiographic signs of these entities and consider them as possible causes of pain as well…

Received January 9, 2009

Hi Pat,

I hope that you are well.

I just thought I would email you personally with information for your file and research that has sadly led to me having a revision from BHR to THR. The reason was due to malpositioning of the acetabular cup and femoral component by my surgeon.

My surgeon had carried out over 480 hip resurfaces but for some reason a bad day at the office lead to my BHR only lasting 5months. I have attached to x-rays (photos of my x-rays). Sorry for bad quality. I had the anterolateral approach. He has been very supportive to me since the extent of the problem was diagnosed and even encouraged me to have my revision with Doctor De Smet. He has told me I was his first problem with hip resurfacing.

I had my revision surgery in Belgium by Doctor De Smet in Dec. He was fantastic and the staff at the Villa were brilliant. It was a very difficult time for me to have my second major surgery in 6 months however Doctor De Smet felt that my original BHR was a disaster (his words) and I was better off not waiting long to have a revision as the steep angle and not being recessed enough was causing muscles and soft tissue damage along with elevated metal ions. Along with the cup malpositioning the femoral head was in an anteverted position causing a tight feeling and making it very difficult to walk straight and without pain.

I am 43 and although I tried to avoid a THR with my hip resurfacing last summer I am now the proud owner of a Wright medical Conserve THR with BFH. I am walking without crutches or cane at 6 weeks. I have learned a lot from this experience. Most of all I have learned that I really should have used the most experienced surgeon I could find first time. I have read so much about this on your web site but it is true. This is a complicated operation for any surgeon. If it goes wrong the revision experience is pretty tough. Please keep preaching this message to people contemplating hip resurfacing.

Well thanks my story and I thought it might interest you with your research.

Best wishes.

John ( Revision) 

Primary Pulmonary Hypertension (PPH) and pulmonary arterial hypertension (PAH) are rare pulmonary diseases that narrow the lung’s blood vessels causing high blood pressure and eventually leading to heart failure. PPH, PAH, and PH have been linked to the use of diet drugs including: Fen-Phen, Redux, Pondimin, may also be caused by consumption of ephedra, ma huang or nutritional supplements such as Metabolife, Herbalife, Dexatrim and herbal products like St John’s Wort extract.

What is Primary Pulmonary Hypertension?

Primary pulmonary hypertension (PPH) is a rare pulmonary disease where progressive narrowing of the blood vessels of the lungs causes high blood pressure in these blood vessels, eventually leading to heart failure. The lungs contain millions of tiny blood vessels called capillaries. These capillaries are extremely small, just wide enough for blood cells to move through. The capillaries are lined with endothelial cells that prevent blood from leaking out of the vessel. Outside of the blood vessels are muscle type cells that expand and contract as blood moves through them from the heart into the lungs. PAH causes the cell lining of the lung’s blood vessels to weaken and allow leakage. The leaking of blood out of the vessels causes the muscles that surround the blood vessels to constrict. This continuous constriction increases the pressure within the blood vessels and cuts off blood flow. The constriction gradually worsens, eventually increasing the pulmonary arterial pressure.

Primary Pulmonary Hypertension Symptoms

The most common symptoms of primary pulmonary hypertension (PPH) or pulmonary arterial hypertension (PAH) include one or more of the following:

• Shortness of breath following exertion
• Excessive fatigue
• Chest pain
• Lightheadedness or dizziness
• Ankle swelling
• Hyperventilation
• Fainting
• Bluish lips and skin (cyanosis)

Diet Drug PPH Lawsuits

Due to the causal connections that have been found to exist between the use of prescription diets pills known as Fen-Phen, Redux, Pondimin and the development of PPH, there have been hundreds of PPH Fen Phen diet drug lawsuits filed against the makers of these dangerous diet drugs. Fen Phen and Redux were taken off the market in the US in 1997. While earlier reports differ, new studies indicate that a PPH diagnosis of ten or more years from the date of the last consumption is well documented. Other causes of PPH may be due to consumption of Ephedra or Ma Huang, nutritional supplements (Metabolife, Herbalife, Dexatrim type of products), St John’s Wort and even cocaine usage. If you have been diagnosed with PPH and took Fen Phen, Redux, Pondimin, Ephedra, Mahuang or St. Johns Wort, then contact our law firm to discuss your legal options.